CorMedix CRMD DefenCath — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about CorMedix's defencath — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CorMedix's defencath — total revenue?
- CorMedix (CRMD) reported defencath — total revenue of $97.51M in Q1 2026.
- How has CorMedix's defencath — total revenue changed year-over-year?
- CorMedix's defencath — total revenue increased by 149.5% year-over-year, from $39.08M to $97.51M.
- What does defencath — total revenue mean?
- This metric represents the total gross revenue generated from the commercial sale of the company's primary therapeutic product, DefenCath. It serves as a key indicator of market adoption, commercial traction, and the effectiveness of the company's go-to-market strategy for its lead asset. Tracking this revenue stream is essential for evaluating the company's transition from a development-stage entity to a commercial-stage biopharmaceutical business.